Manel Juan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3862793/publications.pdf

Version: 2024-02-01

160	8,783	41	89
papers	citations	h-index	g-index
174	174	174	14607
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	13.7	1,364
2	Pyogenic Bacterial Infections in Humans with MyD88 Deficiency. Science, 2008, 321, 691-696.	6.0	844
3	B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunology, 2012, 13, 170-180.	7.0	615
4	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	3.3	488
5	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurology, The, 2018, 17, 760-772.	4.9	422
6	Thyroid Autoimmune Disease. American Journal of Pathology, 2001, 159, 861-873.	1.9	261
7	Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nature Immunology, 2014, 15, 354-364.	7.0	249
8	Cyclooxygenase-2 mRNA Is Downexpressed in Nasal Polyps from Aspirin-sensitive Asthmatics. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 291-296.	2. 5	206
9	Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 2727-2739.	2.6	197
10	Fibronectin Upregulates Gelatinase B (MMP-9) and Induces Coordinated Expression of Gelatinase A (MMP-2) and Its Activator MT1-MMP (MMP-14) by Human T Lymphocyte Cell Lines. A Process Repressed Through RAS/MAP Kinase Signaling Pathways. Blood, 1999, 94, 2754-2766.	0.6	177
11	Lipid transfer protein syndrome: clinical pattern, cofactor effect and profile of molecular sensitization to plantâ€foods and pollens. Clinical and Experimental Allergy, 2012, 42, 1529-1539.	1.4	154
12	Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. Frontiers in Immunology, 2018, 9, 636.	2.2	142
13	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	3.3	112
14	Efficacy of Lowâ€Dose Subcutaneous Interleukinâ€2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus Load. Journal of Infectious Diseases, 1999, 180, 56-60.	1.9	110
15	Expression of the Human Glucocorticoid Receptor \hat{l}_{\pm} and \hat{l}_{2} Isoforms in Human Respiratory Epithelial Cells and Their Regulation by Dexamethasone. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 49-57.	1.4	104
16	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. Aids, 2004, 18, 459-463.	1.0	103
17	Chemokines Determine Local Lymphoneogenesis and a Reduction of Circulating CXCR4+ T and CCR7 B and T Lymphocytes in Thyroid Autoimmune Diseases. Journal of Immunology, 2003, 170, 6320-6328.	0.4	100
18	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796.	0.6	97

#	Article	IF	CITATIONS
19	Similarities and differences between the immunopathogenesis of COVID-19–related pediatric multisystem inflammatory syndrome and Kawasaki disease. Journal of Clinical Investigation, 2021, 131, .	3.9	95
20	The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clinical and Experimental Immunology, 2007, 148, 208-217.	1,1	85
21	Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. American Journal of Transplantation, 2021, 21, 3971-3979.	2.6	85
22	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	3.7	80
23	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	1.8	77
24	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	2.2	77
25	Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Human Molecular Genetics, 2011, 20, 3415-3423.	1.4	74
26	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology, 2018, 29, 2121-2128.	0.6	74
27	Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Scientific Reports, 2019, 9, 18729.	1.6	74
28	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports, 2017, 8, 1573-1586.	2.3	73
29	A somatic <i>NLRP3</i> mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatalâ€onset multisystem inflammatory disease: Novel evidence of the role of lowâ€level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases. Arthritis and Rheumatism, 2010, 62, 1158-1166.	6.7	71
30	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. Cancer, 1994, 73, 2913-2921.	2.0	65
31	mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. Nature Communications, 2017, 8, 1462.	5.8	65
32	CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization and tyrosine phosphorylation through p59fyn and p56lck in Jurkat T cell line Journal of Experimental Medicine, 1994, 179, 1747-1756.	4.2	60
33	LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. European Journal of Human Genetics, 2011, 19, 326-333.	1.4	60
34	DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes. Journal of Allergy and Clinical Immunology, 2017, 139, 202-211.e6.	1.5	57
35	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis and Rheumatism, 1998, 41, 435-444.	6.7	56
36	The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clinical and Experimental Immunology, 2007, 150, 1-12.	1.1	55

#	Article	lF	Citations
37	Immunological Changes in Blood of Newborns Exposed to Anti-TNF- $\hat{l}\pm$ during Pregnancy. Frontiers in Immunology, 2017, 8, 1123.	2.2	51
38	Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in \hat{I}^21 and \hat{I}^22 integrin function. European Journal of Immunology, 1994, 24, 1377-1382.	1.6	50
39	Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. Journal of Autoimmunity, 2005, 25, 312-318.	3.0	50
40	The inflammasome pathway in stable COPD and acute exacerbations. ERJ Open Research, 2016, 2, 00002-2016.	1,1	47
41	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology, 2008, 5, 32.	0.9	46
42	Multiple Products Derived from Two CCL4 Loci: High Incidence of a New Polymorphism in HIV+ Patients. Journal of Immunology, 2005, 174, 5655-5664.	0.4	45
43	Frequency of Antineutrophil Cytoplasmic Antibody in Graves' Disease Patients Treated with Methimazole. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2141-2146.	1.8	44
44	Laboratory evaluation of the IFN- \hat{I}^3 circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 184-204.	2.7	43
45	Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations. Journal of Clinical Immunology, 2020, 40, 987-1000.	2.0	41
46	Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management. Frontiers in Immunology, 2019, 10, 586.	2.2	40
47	Copy number variation in chemokine superfamily: the complex scene of ⟨i⟩CCL3L⟨ i⟩–⟨i⟩CCL4L⟨ i⟩genes in health and disease. Clinical and Experimental Immunology, 2010, 162, 41-52.	1.1	36
48	CDw50 and ICAM-3: Two names for the same molecule. European Journal of Immunology, 1993, 23, 1508-1512.	1.6	34
49	Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis, 1999, 3, 271-280.	3.7	34
50	Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood, 2008, 112, 4337-4342.	0.6	34
51	Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respiratory Research, 2019, 20, 152.	1.4	34
52	B Regulatory Cells: Players in Pregnancy and Early Life. International Journal of Molecular Sciences, 2018, 19, 2099.	1.8	31
53	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2018, 8, 127.	1.3	31
54	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia, 2020, 34, 100-114.	3.3	31

#	Article	IF	CITATIONS
55	Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. International Journal of Molecular Sciences, 2021, 22, 1026.	1.8	31
56	Sirolimus as an alternative treatment in patients with granulomatousâ€lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells. Pediatric Allergy and Immunology, 2018, 29, 425-432.	1.1	30
57	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute, 2022, 114, 436-445.	3.0	29
58	Nonsteroidal antiâ€inflammatory drugs enhance IgEâ€mediated activation of human basophils in patients with food anaphylaxis dependent on and independent of nonsteroidal antiâ€inflammatory drugs. Clinical and Experimental Allergy, 2016, 46, 1111-1119.	1.4	26
59	CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity. Journal of Investigative Dermatology, 2011, 131, 1830-1837.	0.3	25
60	Jug r 2–reactive CD4+ T cells have a dominant immune role in walnut allergy. Journal of Allergy and Clinical Immunology, 2015, 136, 983-992.e7.	1.5	25
61	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica, 2020, 106, 173-184.	1.7	25
62	Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes and Immunity, 2009, 10, 254-259.	2.2	24
63	Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency. European Journal of Pediatrics, 2015, 174, 1069-1076.	1.3	23
64	HLA-B27 genotyping by Fluorescent Resonance Emission Transfer (FRET) probes in real-time PCR. Human Immunology, 2004, 65, 826-838.	1.2	22
65	Reassessing the role of HLAâ€DRB3 Tâ€cell responses: Evidence for significant expression and complementary antigen presentation. European Journal of Immunology, 2010, 40, 91-102.	1.6	21
66	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
67	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy, 2022, 30, 550-563.	3.7	21
68	Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop. Human Immunology, 2019, 80, 449-460.	1.2	20
69	CD34+CD19â^'CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	0.6	20
70	Regulation of ICAM-3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1293-1298.	2.7	19
71	Population structure in copy number variation and SNPs in the CCL4L chemokine gene. Genes and Immunity, 2008, 9, 279-288.	2.2	19
72	Characterization of the Highly Prevalent Regulatory CD24hiCD38hi B-Cell Population in Human Cord Blood. Frontiers in Immunology, 2017, 8, 201.	2.2	19

#	Article	IF	CITATIONS
73	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. Frontiers in Oncology, 2022, 12, 828471.	1.3	19
74	Serum allergenâ€specific <scp>l</scp> g <scp>A</scp> is not associated with natural or induced tolerance to egg in children. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1327-1332.	2.7	18
75	Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development. Leukemia, 2016, 30, 1603-1606.	3.3	18
76	Toll-like receptor 3 deficiency in autoimmune encephalitis post–herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e611.	3.1	18
77	The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplantation, 2022, 57, 156-159.	1.3	18
78	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
79	Stimulation through CD50 (ICAMâ€3) induces both activation and programmed cell death of human thymocytes. Tissue Antigens, 1996, 48, 626-635.	1.0	16
80	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2064-2068.	0.6	16
81	Association of Polymorphisms in IRAK1, IRAK4 and MyD88, and Severe Invasive Pneumococcal Disease. Pediatric Infectious Disease Journal, 2015, 34, 1008-1013.	1.1	16
82	Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. , 2020, 8, e001419.		16
83	Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001. Human Gene Therapy, 2021, 32, 1004-1007.	1.4	16
84	Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology, 2017, 222, 620-630.	0.8	15
85	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells, 2020, 9, 203.	1.8	15
86	CD137 Costimulation Counteracts TGF \hat{l}^2 Inhibition of NK-cell Antitumor Function. Cancer Immunology Research, 2021, 9, 1476-1490.	1.6	15
87	CD50 (intercellular adhesion moleculeâ€3) is expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets. Tissue Antigens, 1995, 46, 32-44.	1.0	14
88	Development of a new HLA-DRB real-time PCR typing method. Human Immunology, 2005, 66, 85-91.	1.2	14
89	Atypical lymphoid cells circulating in blood in COVID-19 infection: morphology, immunophenotype and prognosis value. Journal of Clinical Pathology, 2022, 75, 104-111.	1.0	14
90	ANCA antibodies in Graves' disease. Annals of the Rheumatic Diseases, 2002, 61, 90-91.	0.5	13

#	Article	IF	CITATIONS
91	Single-cycle rituximab-induced immunologic changes in children. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	13
92	Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time― Central Versus Point of Care Proposals. Frontiers in Immunology, 2020, 11, 573179.	2.2	12
93	Recurrent Invasive Pneumococcal Disease in Children: Underlying Clinical Conditions, and Immunological and Microbiological Characteristics. PLoS ONE, 2015, 10, e0118848.	1.1	12
94	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. Cancer Immunology Research, 2022, 10, 498-511.	1.6	12
95	Evans Syndrome as First Manifestation of Primary Immunodeficiency in Clinical Practice. Journal of Pediatric Hematology/Oncology, 2017, 39, 490-494.	0.3	11
96	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2021, 56, 376-386.	1.3	11
97	Enforced sialylâ€Lewisâ€X (sLeX) display in Eâ€selectin ligands by exofucosylation is dispensable for CD19â€CAR Tâ€cell activity and bone marrow homing. Clinical and Translational Medicine, 2021, 11, e280.	1.7	11
98	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy., 2021, 9, e003644.		11
99	Real-Time PCR Using Fluorescent Resonance Emission Transfer Probes for HLA-B Typing. Human Immunology, 2006, 67, 374-385.	1.2	10
100	Massively parallel sequencing reveals maternal somatic IL2RG mosaicism in an X-linked severe combined immunodeficiency family. Journal of Allergy and Clinical Immunology, 2013, 132, 741-743.e2.	1.5	10
101	Purification, Culture, and CD19 AR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Current Protocols in Immunology, 2020, 131, e108.	3.6	10
102	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. Cancers, 2021, 13, 4664.	1.7	10
103	Expression of intercellular adhesion moleculeâ€3 (ICAMâ€3/CD50) in malignant lymphoproliferative disorders and solid tumors. Tissue Antigens, 1996, 48, 271-277.	1.0	9
104	One-tube-PCR technique for CCL2, CCL3, CCL4 and CCL5 applied to fine needle aspiration biopsies shows different profiles in autoimmune and non-autoimmune thyroid disorders. Journal of Endocrinological Investigation, 2006, 29, 342-349.	1.8	9
105	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. Turkish Journal of Haematology, 2018, 35, 217-228.	0.2	9
106	CART manufacturing process and reasons for academy-pharma collaboration. Immunology Letters, 2020, 217, 39-48.	1.1	9
107	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines, 2022, 10, 537.	1.4	9
108	Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12RÎ ² 1-Deficient Peruvian Girl. Journal of Clinical Immunology, 2018, 38, 712-716.	2.0	8

#	Article	IF	Citations
109	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813.	1.1	8
110	Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches Allergologia Et Immunopathologia, 2021, 49, 118-127.	1.0	8
111	Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2837-2837.	0.6	8
112	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. British Journal of Haematology, 2018, 181, 133-137.	1.2	7
113	Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling. Stem Cells, 2019, 37, 476-488.	1.4	7
114	Autoimmune biomarkers in portoâ€sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. Liver International, 2021, 41, 2171-2178.	1.9	7
115	From Primary Immunodeficiency to Autoimmunity: How Extreme Situations Highlight the Main Genetic Factors Involved in Autoimmune Disease. MOJ Immunology, 2016, 4, .	11.0	7
116	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers, 2021, 13, 5418.	1.7	7
117	CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. Blood, 2021, 138, 735-735.	0.6	7
118	Novel and atypical splicing mutation in a compound heterozygous UNC13D defect presenting in Familial Hemophagocytic Lymphohistiocytosis triggered by EBV infection. Clinical Immunology, 2014, 153, 292-297.	1.4	6
119	Results of <scp>ARI</scp> â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp> â€positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	2.0	6
120	Humoral deficiency in three paediatric patients with genetic diseases. Allergologia Et Immunopathologia, 2016, 44, 257-262.	1.0	5
121	Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia. HemaSphere, 2019, 3, e174.	1.2	5
122	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS ONE, 2016, 11, e0166631.	1,1	5
123	Mapping of Helper Epitopes to HPA-1a in Neonatal Alloimmune Thrombocytopenia with T-Cell Clones. Blood, 2008, 112, 3040-3040.	0.6	4
124	Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology, 2020, 11, 898-917.	0.9	4
125	Abstract OT1-01-01: SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. Cancer Research, 2020, 80, OT1-01-01-01-01.	0.4	4
126	Physiological lentiviral vectors for the generation of improved CAR-T cells. Molecular Therapy - Oncolytics, 2022, 25, 335-349.	2.0	4

#	Article	IF	Citations
127	CAR T cells targeting options in the fight against multiple myeloma. Panminerva Medica, 2021, 63, 37-45.	0.2	2
128	Correlative Biological Studies Related to the Response, Peak and Persistence of ARIO002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2021, 138, 552-552.	0.6	2
129	CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood. Frontiers in Immunology, 0, 13, .	2.2	2
130	Rsal polymorphism of the human CD27 gene, a member of nerve growth factor receptor gene family. Human Molecular Genetics, 1992, 1, 660-660.	1.4	1
131	Isolation of two CD50 (ICAMâ€3)â€negative Jurkat Tâ€cell clones and their application for analysis of CD50 function. Tissue Antigens, 1998, 51, 509-519.	1.0	1
132	InmunologÃa y los Premios Nobel 2011. Inmunologia (Barcelona, Spain: 1987), 2012, 31, 1-3.	0.1	1
133	Type I leucocyte adhesion deficiency (LAD I). Report of a case. Allergologia Et Immunopathologia, 2012, 40, 254-258.	1.0	1
134	Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing. Translational Medicine Communications, 2020, 5, .	0.5	1
135	41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1). Annals of Oncology, 2020, 31, S30.	0.6	1
136	InmunologÃa en COVID-19; mucho más allá del diagnóstico de la infección o de la vacunación. Medicina ClÃnica, 2021, 158, 324-324.	0.3	1
137	SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae. ERJ Open Research, 2022, 8, 00706-2021.	1.1	1
138	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. Cancer Research, 2022, 82, P2-14-13-P2-14-13.	0.4	1
139	Otro signo de identidad de nuestra sociedad: GECLID-SEI. Inmunologia (Barcelona, Spain: 1987), 2011, 30, 77-78.	0.1	0
140	A SNP in intron 1 of TSHR controls its thymic expression and susceptibility to Graves $\hat{a} \in \mathbb{N}$ disease suggesting central tolerance failure in pathogenesis. Journal of Translational Medicine, 2011, 9, .	1.8	0
141	Pathogenic Mechanisms and Clinical Relevance of Autoantibodies. , 2014, , 51-57.		O
142	Neutrophil function in patients with chronic hepatitis C (CHC) undergoing triple antiviral therapy (TT) with first and second generation protease inhibitors (PI). Digestive and Liver Disease, 2015, 47, e37.	0.4	0
143	Mutations in the Toll-like receptor/MYD88 pathway in young (â‰\$0 years) CLL patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S203.	0.2	0
144	Characterization of TCR repertoire of CD4+ and CD8+ T cells from patients with multiple myeloma in sustained complete remission. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e226-e227.	0.2	0

#	Article	IF	CITATIONS
145	Clues to management of neonatally diagnosed <scp>BTK</scp> deficiency. Pediatric Allergy and Immunology, 2016, 27, 428-430.	1.1	0
146	Elimination of Anti-HLA Alloantibody Producing B Cells through the Use of a CAR-Like HLA Molecule in T Cells. Transplantation, 2017, 101, S17.	0.5	0
147	DIPG-08. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2017, 19, iv6-iv6.	0.6	0
148	DIPG-18. IMMUNE RESPONSE GENERATED WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIPG. Neuro-Oncology, 2018, 20, i52-i52.	0.6	0
149	109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types. Annals of Oncology, 2020, 31, S284-S285.	0.6	0
150	CAR-T immunotherapy in paediatric haemato-oncology… present and future. Anales De PediatrÃa (English Edition), 2020, 93, 1-3.	0.1	0
151	Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis. Blood, 2010, 116, 1389-1389.	0.6	0
152	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. Blood, 2015, 126, 4192-4192.	0.6	0
153	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis Journal of Clinical Oncology, 2016, 34, 3033-3033.	0.8	0
154	Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD. , 2017, , .		0
155	Abstract LB-083: Targeting IRAK4 disrupts inflammatory pathways and tumor microenvironment in chronic lymphocytic leukemia regardless MYD88 mutational status. , 2018, , .		0
156	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650.	0.6	0
157	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients Journal of Clinical Oncology, 2019, 37, 207-207.	0.8	0
158	Design and <i>in Vitro</i> Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	0.6	0
159	806â€Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. , 2020, , .		0
160	Immunology in COVID-19; more than diagnosis of infection or the basis of vaccination. Medicina ClÃnica (English Edition), 2022, 158, 324-324.	0.1	0